<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Favipiravir was highlighted as a treatment during the lethal Ebola virus epidemic in West Africa in 2014 because a standard treatment for lethal Ebola virus infection is not available. Favipiravir has been reported to be effective for prophylaxis and treating lethal Ebola virus infection in animal models (
 <xref rid="bb0430" ref-type="bibr">Oestereich et al., 2014</xref>; 
 <xref rid="bb0550" ref-type="bibr">Smither et al., 2014</xref>) and is licensed for influenza treatment based on its confirmed safety and efficacy in clinical trials in humans. Based on this information, favipiravir was successfully used for the post-exposure prophylaxis and treatment of patients with Ebola virus infection (
 <xref rid="bb0030" ref-type="bibr">Bai et al., 2016</xref>; 
 <xref rid="bb0265" ref-type="bibr">Jacobs et al., 2015</xref>; 
 <xref rid="bb0540" ref-type="bibr">Sissoko et al., 2016</xref>).
</p>
